Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals

Background Plasma biomarkers have shown promising for identification of patients with Alzheimer’s Disease (AD), but whether this holds for the earliest preclinical stages needs further study. We aimed to investigate the predictive value of plasma amyloid‐β1‐42/1‐40 and glial fibrillary acidic protein (GFAP) for identifying amyloid pathology in cognitively unimpaired individuals. We tested this using plasma samples collected at time of CSF/PET amyloid assessment and, using plasma samples collected 10 years before CSF/PET amyloid assessment. Methods We selected 151 subjects with normal cognition from the EMIF‐AD PreclinAD study. Amyloid status was defined using visual read of dynamic [18F]flutemetamol PET images or CSF amyloid‐β1‐42/1‐40 (Euroimmun)